Multiple Sclerosis (Ms) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.[1]
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative disease of the [central nervous system] characterized by demyelination, axonal damage, and progressive neurological disability. The disease involves the immune system attacking the [myelin] sheath that insulates nerve fibers, leading to disrupted communication between the brain and the rest of the body. MS is one of the most common causes of neurological disability in young adults, typically presenting between ages 20 and 40 (Filippi et al., 2018).
MS shares important pathological features with other neurodegenerative diseases, including [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--, [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX--, and progressive neuronal loss. Understanding MS has provided critical insights into the role of [microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX--; Atlas of MS, 2024. The incidence rate is approximately 2.1 per 100,000 persons per year, with a mean age of diagnosis around 32 years (Walton et al., 2020).
Key epidemiological features include:
- Gender disparity: Women are 2–3 times more likely to develop MS than men, with the female-to-male ratio increasing over recent decades (Koch-Henriksen & Sørensen, 2010)
- Geographic gradient: Prevalence increases with distance from the equator. Countries with the highest prevalence include Sweden (219/100,000), Canada (182/100,000), Norway (176/100,000), and Ireland (163/100,000) (Atlas of MS, 2024)
- Rising prevalence: Global prevalence has increased by approximately 26% over the past three decades, likely due to improved diagnostics and increased survival (Walton et al., 2020)
- Age of onset: Most commonly between 20–40 years, though pediatric and late-onset MS also occur
MS is classified into four major clinical subtypes based on disease course:
The most common form, affecting approximately 85% of patients at diagnosis. RRMS is characterized by clearly defined episodes of acute neurological dysfunction (relapses) followed by partial or complete recovery (remissions). Between relapses, the disease does not progress (Lublin et al., 2014).
Approximately 50–65% of RRMS patients eventually transition to SPMS, characterized by gradual accumulation of disability independent of relapses. This transition typically occurs 10–20 years after initial RRMS diagnosis (Lublin et al., 2014).
Affects approximately 10–15% of patients, characterized by steady accumulation of disability from disease onset without distinct relapses or remissions. PPMS tends to have equal sex distribution and later onset than RRMS (Ontaneda et al., 2017).
The rarest form, characterized by steady disease progression from onset with occasional acute relapses. This subtype is now often reclassified under the revised 2013 phenotype descriptions as PPMS with active disease (Lublin et al., 2014).
The hallmark of MS pathology is the formation of demyelinating lesions (plaques) in the [cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, periventricular white matter, optic nerves, brainstem, [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--, and spinal cord. The pathological process involves:
- Peripheral activation: Autoreactive [T cells]microglia/Compston & Coles, 2008))
- [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breach: Activated T cells cross the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- by interacting with adhesion molecules on endothelial cells
- Local reactivation: Once in the CNS, T cells are reactivated by myelin antigens presented by local [microglia/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, releasing pro-inflammatory cytokines (IFN-γ, IL-17, TNF-α, IL-6) (Dendrou et al., 2015)
- Demyelination: The inflammatory cascade recruits macrophages and activates resident [microglia/reactive oxygen species] and nitric oxide
B cells play a multifaceted role in MS pathogenesis beyond simple antibody production. B cells act as antigen-presenting cells, produce pro-inflammatory cytokines (TNF-α, IL-6, GM-CSF), and form ectopic lymphoid follicles in the meninges. The striking efficacy of anti-CD20 therapies (ocrelizumab, rituximab, ofatumumab) has underscored the central role of B cells (Hauser et al., 2017).
Beyond demyelination, MS involves significant neurodegenerative processes:
- Axonal transection: Occurs early in lesion formation and correlates with inflammatory cell density (Trapp et al., 1998)
- Cortical demyelination: Subpial cortical lesions are a hallmark of progressive MS and correlate with disability
- Brain atrophy: Progressive brain volume loss occurs at 0.5–1.0% per year in MS patients (vs. 0.1–0.3% in age-matched controls)
- Mitochondrial dysfunction: Impaired [mitochondrial] respiratory chain activity contributes to energy failure and neuronal vulnerability (Campbell et al., 2011)
- [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--: Free radical damage from activated immune cells and dysfunctional mitochondria drives neuronal injury
- Iron accumulation: Progressive MS is associated with pathological iron deposition in gray matter, contributing to oxidative damage
[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- progenitor cells (OPCs) are present in MS lesions but often fail to differentiate into mature myelinating oligodendrocytes. Factors contributing to remyelination failure include:
- Inhibitory signals in the lesion environment (e.g., LINGO-1, Notch signaling)
- Astrocytic scarring forming a physical barrier
- Age-related decline in OPC regenerative capacity
- Chronic inflammation creating a hostile environment for remyelination
MS is a polygenic disease with both genetic and environmental contributions. The estimated heritability is approximately 50%, with concordance rates of 25–30% in monozygotic twins (International Multiple Sclerosis Genetics Consortium, 2019).
The strongest genetic risk factor is the [HLA-DRB1[/genes/[hla-drb1[/genes/[hla-drb1[/genes/[hla-drb1--TEMP--/genes)--FIX--15:01 allele in the major histocompatibility complex (MHC) region on chromosome 6p21. [Carrying one copy of HLA-DRB115:01 increases MS risk approximately threefold, and the HLA region explains approximately 10.5% of the genetic variance underlying MS risk (Moutsianas et al., 2015).
Genome-wide association studies (GWAS) have identified over 200 non-HLA genetic variants associated with MS risk. These predominantly involve genes related to immune function, including:
- IL-2RA and IL-7RA: Interleukin receptor genes involved in T-cell homeostasis
- CD58: Adhesion molecule involved in T-cell activation
- CLEC16A: Involved in [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- and immune cell function
- EVI5: Cell cycle regulator expressed in T cells
- TYK2: Signaling molecule in the JAK-STAT pathway
EBV infection is the strongest environmental risk factor for MS. A landmark study showed that EBV infection increases MS risk more than 30-fold (Bjornevik et al., 2022). The mechanism may involve molecular mimicry between EBV nuclear antigen 1 (EBNA1) and the CNS autoantigen GlialCAM (Lanz et al., 2022).
Low vitamin D levels are associated with increased MS risk and disease activity. The VDR gene has a vitamin D response element in the HLA-DRB1 promoter region, providing a direct mechanistic link between vitamin D, HLA genetics, and MS susceptibility (Ramagopalan et al., 2009).
- Smoking: Increases MS risk by approximately 1.5-fold and accelerates disease progression
- Obesity in adolescence: Associated with approximately doubled MS risk
- Geographic latitude: Higher latitudes correlate with higher prevalence, likely mediated by vitamin D
- Gut [microbiome[/entities/[microbiome[/entities/[microbiome[/entities/[microbiome--TEMP--/entities)--FIX--: Altered gut microbial composition has been observed in MS patients, suggesting a role for the [Gut-Brain Axis[/mechanisms/[gut-brain-axis[/mechanisms/[gut-brain-axis[/mechanisms/[gut-brain-axis--TEMP--/mechanisms)--FIX--
MS diagnosis relies on the McDonald Criteria (revised 2017), which require demonstration of CNS lesions disseminated in space and time (Thompson et al., 2018):
- MRI: The primary diagnostic tool, showing characteristic T2-hyperintense and gadolinium-enhancing lesions in typical CNS locations (periventricular, cortical/juxtacortical, infratentorial, spinal cord)
- Cerebrospinal fluid (CSF): Oligoclonal bands present in >95% of MS patients; can substitute for dissemination in time
- Evoked potentials: Visual evoked potentials can detect subclinical optic nerve demyelination
- [Biomarkers]: [Neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- levels in CSF and serum correlate with axonal damage and disease activity; [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- is emerging as a marker of astrocytic damage
DMTs are the cornerstone of MS treatment, aiming to reduce relapse frequency, slow disability accumulation, and limit new MRI lesions. They are classified by efficacy:
- Interferon-β (IFN-β): Betaferon, Avonex, Rebif — reduce relapse rate by approximately 30% via immunomodulatory effects
- Glatiramer acetate (Copaxone): Synthetic peptide polymer that modulates T-cell responses
- Teriflunomide (Aubagio): Oral DHODH inhibitor that reduces T- and B-cell proliferation
- Dimethyl fumarate (Tecfidera): Oral Nrf2 activator with anti-inflammatory and neuroprotective properties
- Natalizumab (Tysabri): Anti-α4-integrin monoclonal antibody that blocks lymphocyte migration across the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--; risk of progressive multifocal leukoencephalopathy (PML) in JC-virus-positive patients
- Ocrelizumab (Ocrevus): Anti-CD20 monoclonal antibody; the first DMT approved for both RRMS and PPMS (Hauser et al., 2017)
- Ofatumumab (Kesimpta): Subcutaneous anti-CD20 monoclonal antibody for self-administration
- Ublituximab (Briumvi): Anti-CD20 monoclonal antibody with enhanced ADCC activity
- Fingolimod (Gilenya): Oral sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymph nodes
- Siponimod (Mayzent): Selective S1P1,5 receptor modulator; specifically approved for SPMS
- Ozanimod (Zeposia): Next-generation S1P receptor modulator
- Cladribine (Mavenclad): Oral purine analogue that selectively depletes lymphocytes
- Alemtuzumab (Lemtrada): Anti-CD52 monoclonal antibody; highly effective but risk of secondary autoimmunity
- Spasticity: Baclofen, tizanidine, gabapentin, dantrolene, benzodiazepines, nabiximols (Sativex)
- Fatigue: Amantadine, modafinil, physical rehabilitation
- Pain: Gabapentin, pregabalin, carbamazepine (for trigeminal neuralgia), duloxetine
- Bladder dysfunction: Anticholinergics, desmopressin, intermittent self-catheterization
- Depression: SSRIs, SNRIs, cognitive behavioral therapy
- Bruton's tyrosine kinase (BTK) inhibitors: Tolebrutinib, fenebrutinib, and evobrutinib are in Phase III trials targeting CNS-resident B cells and [microglia.
Following the demonstration that EBV is likely a necessary cause of MS, therapeutic strategies targeting EBV are under investigation, including antiviral agents and EBV-specific T-cell therapies (Bar-Or et al., 2024).
¶ Understanding Progressive MS
Research is focused on understanding the mechanisms driving progression independent of relapse activity (PIRA), including chronic active lesions ("smoldering" plaques), meningeal inflammation, and [mitochondrial] dysfunction. Paramagnetic rim lesions (PRLs) on MRI are being studied as imaging biomarkers for chronic active inflammation.
The study of Multiple Sclerosis (Ms) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Filippi et al., Multiple sclerosis (2018)
- Walton et al., Global prevalence of multiple sclerosis (2020)
- Koch-Henriksen & Sørensen, The changing demographic pattern of MS (2010)
- Atlas of MS (2024)
- Roxburgh et al., Multiple Sclerosis Severity Score (2005)
- Confavreux & Vukusic, Age at onset of MS (2006)
- Lublin & Reingold, Defining the clinical course of MS (1996)
- Hollenbach & Oksenberg, The immunogenetics of MS (2015)
- Dendrou et al., Immunopathology of MS (2015)
- [Astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- [Oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX--
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia
- [Treatments Index/treatments)